An Independent Analysis of the Manufacturing and Quality Issues of the BNT162b BioNTech/Pfizer Quasi-vaccine Based on the European Medicines Agency’s Public Assessment Report (EPAR)

L. Maria Gutschi et al.

This article summarizes the main findings of a more detailed technical assessment concerning the development and manufacturing of the BioNTech/Pfizer’s COVID-19 quasi-vaccine BNT162b. A number of deficiencies in the product’s development were identified by regulatory agencies and appear to have either been ignored or glossed over. Vaccine approval for the declared COVID-19 pandemic was given ‘fast-track ’conditional approval to address “a seriously debilitating, rare or life-threatening disease devoid of a viable treatment” and approval was granted on the condition that additional information would be forthcoming after the vaccine was rolled out. This data has not been fully provided to date.

Latest articles

Dawn Lester & David Parker … As we have shown in many...
Dawn Lester & David Parker Modern medicine is widely acclaimed as being...
Dawn Lester & David Parker In parts one and two, we showed...
Dawn Lester & David Parker In the three previous parts of this...
Roger Koops For those who may not recall Chicken Little (AKA Henny...
Tristan Coleman Does the latest ‘climate consensus’ study show a genuine agreement...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!